Sakar Healthcare share news and announcements
NSE: SAKARPharmaceuticals & BiotechnologySmall Cap
Last close ₹889.80down ₹62.00 (6.51%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹951.80.
52-week range of traded prices to 23 Oct 2026
₹352.00Low, 27 Oct 2025₹1,229.85High, 23 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 23 Oct 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,980 Cr1,357th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 23 Oct 2026
- 46.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 Oct 2026
- 5.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 23 Oct 2026
- 13.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 23 Oct 2026
- 16.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 23 Oct 2026
- 0.13
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,47,09017.5% delivered
Sakar Healthcare share news and announcements
453 announcements, routine notices left out, newest first. Page 8 of 10.
Dec 2019
2 Dec · Legal
Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2019
14 Nov · Board meeting
Oct 2019
Sep 2019
13 Sep · Board meeting
Aug 2019
Jul 2019
24 Jul · Updates
Jun 2019
May 2019
Apr 2019
Jan 2019
Dec 2018
10 Dec · Meeting
10 Dec · Board meeting
Nov 2018
29 Nov · Board meeting
5 Nov · Board meeting
3 Nov · Board meeting
Oct 2018
31 Oct · Board meeting
11 Oct · Board meeting
Sep 2018
Aug 2018